It has been suggested that, although the newly formed bone at the tumour periphery allows for a sufficient mechanical scaffold for curettage to be done without fear of the bone collapsing, this rim of sclerotic bone may contain neoplastic stromal cells that may become active and express RANKL after denosumab treatment is stopped [36]. This evidence concerns the gene TNFSF11 and neoplasm.